Seladelpar Could 'Raise the Bar' in PBC Treatment : vimarsana.com

The investigational agent significantly improved liver biomarkers of disease activity and symptoms of pruritus in adults with PBC enrolled in a phase 3 trial.

Related Keywords

Toronto , Ontario , Canada , United States , Connecticut , New Haven , American , Gideon Hirschfield , Davidn Assis , Toronto Center , Yale School Of Medicine , Drug Administration , Liver Disease , Toronto General Hospital , Medscape Medical , Cymabay Therapeutics , New England Journal , Liver Meeting , American Association , Digestive Diseases , Yale School , Cymabay Therapeutic , Child Pugh , Biliary Disease , Allbladder Disease , Pruritus , Ruritis , Tch , Cholangitis , Liver , Aminotransferase , St , Iver Enzymes , Iver Studies , Olt , Ransaminase , Epatic Impairment , Pain Management , Patient Safety , Biomarker , Iological Marker , Ulti Biomarker Disease Activity , Bda , Ultibiomarker Disease Activity , Peroxisome Proliferator Activated Receptor Agonists , Par Agonists ,